

TABLE OF CONTENTS

LIST OF FIGURES	V
LIST OF TABLES	VII
SUMMARY	VIII
ACKNOWLEDGEMENT	X
1 INTRODUCTION	1
2 REVIEW OF LITERATURE	
2.1 Erythropoietin	3
2.2 Discovery of EPO	4
2.3 Gene of EPO	4
2.3.1 Site of EPO production	6
2.4 Protein of EPO	6
2.4.1 Description of protein	6
2.4.2 Structure of EPO protein	7
2.4.3 Post translational modification	8
2.5 Receptor of EPO	9
2.6 Signaling cascade triggered by EPO	10
2.7 Action of EPO on erythropoietic progenitor cells	10
2.8 Non- erythropoietic actions of EPO	12
2.9 Available types of recombinant human EPO	14
2.10 Uses of recombinant human EPO	16
2.10.1 Use of rHuEPO in renal disease	16
2.10.2 Use of rHuEPO in cancer and other chronic diseases	16
2.10.3 Use of rHuEPO in hematologic malignancies	16
2.10.4 Use of rHuEPO in cardiac diseases	18
2.10.5 Use of rHuEPO as neuroprotective agent	19
2.11 Importance of glycosylation in therapeutic proteins	19
2.11.1 The role of glycosylation in pharmacokinetics	20
2.11.2 The role of glycosylation for tissue targeting	21
2.11.3 The role of glycosylation for modulating biological activity	21
2.11.4 Glycosylation protect protein from proteases attack	22
2.12 Choosing the perfect expression systems to produce glycoprotein	22
2.12.1 Bacterial expression systems	22
2.12.2 Yeast expression systems	23
2.12.3 Plant based expression systems	24
2.12.4 Insects cells	25
2.12.5 Baby hamster kidney cells	25
2.12.6 Chinese hamster ovary cells	26
2.12.7 Human cell lines	28

2.12.8	Transgenic animals	30
2.13	Transient transfection	30
2.13.1	Large-scale transient transfection	31
2.14	Stable transfection	32
3	MATERIALS AND METHODS	
3.1	Addition of secretory signal at 5' end of EPO gene	35
3.1.1	Source of plasmid	35
3.1.2	Designing of over lapping primer	35
3.1.3	PCR amplification of EPO gene using over lapping primer	37
3.1.4	Gel electrophoresis	38
3.1.5	Purification of PCR products through gel elution	38
3.2	Cloning of EPO-cDNA constructs into pCR2.1 vector	39
3.2.1	Ligation reaction	40
3.2.2	Competent cell preparation	40
3.2.3	Heat shock transformation	41
3.2.4	Plasmid DNA isolation (Miniprep)	41
3.2.5	Confirmation of pCR2.1 vector with inserts	42
3.3	Sequencing PCR	43
3.3.1	Ethanol precipitation of the sequencing PCR product	44
3.3.2	Sequence analysis	44
3.4	Sub-cloning of EPO-cDNA constructs into mammalian expression plasmid	44
3.4.1	Restriction digestion	45
3.4.2	Restricted DNA purification through gel elution	46
3.4.3	Ligation of EPO-cDNA construct into pcDNA3.1	46
3.4.4	Heat shock transformation and Miniprep plasmid isolation	46
3.4.5	Confirmation of the cloned EPO gene in mammalian expression vector	47
3.5	Maxi preparation plasmid DNA	47
3.6	Cultivation of cells	48
3.6.1	Huh-7 cells	48
3.6.2	CHO cells	48
3.6.3	Cell splitting and plating	49
3.7	Transient transfection of EPO cDNA constructs	49
3.8	Stable transfection of EPO gene in both cell lines	49
3.8.1	Toxicity analysis of CHO and Huh-7 cell line for Zeocin	50
3.8.2	Plasmid linearization	50
3.8.3	Transfection and drug selection	52
3.8.4	Isolation of Zeocin resistant clones	52

3.9	Total RNA isolation from transfected cells	53
3.9.1	First method for RNA isolation	53
3.9.2	Second method for RNA isolation	54
3.10	Semi-quantitative RT-PCR	54
3.10.1	Primer designing for RT-PCR	54
3.10.2	Synthesis of cDNA	55
3.10.3	PCR amplification for RT-PCR	55
3.11	ELISA (Enzyme Liked Immunosorbent assay)	57
3.12	Western blotting	57
3.12.1	Intra-cellular protein isolation and media collection	57
3.12.2	Sample preparation	58
3.12.3	SDS gel electrophoresis	58
3.12.4	Transfer and blocking to membrane	59
3.12.5	Antibody incubations	60
3.12.6	ECL viewing	60
3.13	Statistical analysis	60
4	RESULTS	
4.1	Construction of expression vectors for erythropoietin gene expression analysis	61
4.1.1	Addition of secretary signal sequences at 5'end of EPO gene	61
4.1.2	Addition of Kozak sequences at 5'end of EPO gene	62
4.1.3	Cloning of EPO-cDNA constructs into pCR2.1	63
4.1.4	PCR confirmation of secretary signal addition	65
4.1.5	Sub-cloning of EPO-cDNA constructs into mammalian expression vector pcDNA3.1	66
4.1.5.1	Restriction digestion	66
4.1.5.2	Ligation	67
4.1.5.3	Cloning confirmation	67
4.1.6	Maxi preparation of EPO expression plasmids	68
4.2	Comparative expression analysis of all three EPO-cDNA constructs in CHO cell line	71
4.2.1	Expression analysis of all three EPO-cDNA constructs through RT-PCR	71
4.2.2	Expression analysis of all three EPO-cDNA constructs through ELISA	72
4.3	Comparative expression analysis of EPO in CHO and Huh-7 cell line	74
4.3.1	Comparative expression of EPO at mRNA level through RT-PCR	74
4.3.2	Comparative expression analysis of EPO at protein level through ELISA and western blot	75

4.4	Generation of stable cell line for continuous production of erythropoietin	77
4.4.1	Plasmid linearization	77
4.4.2	Stable transfection	78
4.4.3	Screening of clones for highest expression of EPO through RT-PCR analysis	79
4.4.4	Screening of stable clones for highest EPO expression through western blot analysis	82
4.5	Persistent expression of EPO up to 17 passages with and without selection pressure	84
5	DISCUSSION	86
6	REFERENCES	93
7	APPENDICES	116